




PIPELINE

Candidate: Lasofoxifene – Oral SERM

Monotherapy ●
 Combination Therapy ●●

► Breast Cancer

	Preclinical	Phase 1	Phase 2	Phase 3
●	ELAINE 1: Lasofoxifene vs. Fulvestrant 			
●●	ELAINE 2: Laso + Abemaciclib 			
●●	ELAINE 3: (Registrational) Laso + Abema vs. Abema 			
●●	Laso + mTOR Inhibitor			
●●	Laso + SARM			

In Planning
 Enrollment Complete

Lilly

Lilly

tbcrc

▶ Treatment Resistant Tumors (non-ESR1^{mut}) and ESR1^{mut}

•

Laso vs. Fulv

••

Laso + Palbo
vs. Fulv + Palbo

▶ Gynecological Cancer

•/••

Lasofloxifene –
Endometrial
Cancer

▶ ESR1 Assay

Research Assay

Clinical Trial
Assay (CTA)

CTA/CDx

THE UNIVERSITY OF
CHICAGO

UNIVERSITY OF UTAH
 HUNTSMAN
CANCER INSTITUTE